Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 122 от 154

Активно (без набиране) Фаза 3

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Fabry Disease

This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age with Fabry disease who are treatment-naïve or untreated for at least 6 months. * Study visits will take place approximately every 3 months. * The double-blind period will be followed by an open-label extension (OLE) during which participants who have completed the double-blind period will be treated with venglustat for an additional 12 months or until the Common Study End of Treatment Day (CSEOTD).

Начало: 11.03.2022 Край: 04.01.2027 Възраст: от 16 г. Лечение

Argentina, Australia, Brazil +16 Sanofi NCT05206773

Активно (без набиране) Фаза 3

Statin TReatment for COVID-19 to Optimise NeuroloGical recovERy

Neurocognitive Impairment, Mild

STRONGER is an international, investigator initiated and conducted, pragmatic clinical trial to determine whether 40mg atorvastatin daily can improve neurocognitive function in adults with long COVID neurological symptoms. The objective is to determine effectiveness of treatment with 40mg atorvastatin over 12 months on attenuating cognitive decline and neuroinflammatory biomarkers in adults with long COVID neurological symptoms. The study design is a prospective, randomised, open-label, blinded endpoint (PROBE) study of atorvastatin 40mg on top of standard care, in patients with long COVID neurological symptoms.

Начало: 10.03.2022 Край: 30.07.2025 Възраст: от 18 г. Лечение

Australia The George Institute NCT04904536

Активно (без набиране) Фаза 3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Gastric Cancer Gastroesophageal Junction Adenocarcinoma

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with FGFR2b ≥10% 2+/3+ tumor cell staining (FGFR2b ≥10% 2+/3+TC)

Начало: 07.03.2022 Край: 20.06.2026 Възраст: 18–100 г. Лечение

Argentina, Australia, Belgium +33 Amgen NCT05052801

Активно (без набиране) Фаза 2

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.

Начало: 03.03.2022 Край: 30.01.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +16 GlaxoSmithKline NCT05064358

Активно (без набиране) Фаза 3

PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Prostate Cancer

This clinical trial will evaluate PSMA PET additive value for significant prostate cancer (sPCa) diagnosis in men with negative/equivocal MRI

Начало: 02.03.2022 Край: 01.08.2027 Възраст: от 18 г. Диагностика

Australia Peter MacCallum Cancer Centre, Australia NCT05154162

Активно (без набиране) Фаза 2/3

Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine

COVID-19

A study to assess the effect of varying the time interval between doses on the immunogenicity of an adjuvanted recombinant spike protein Covid-19 vaccine (Spikogen/Covax-19)

Начало: 01.03.2022 Край: 06.10.2024 Възраст: от 18 г. Превенция

Australia Vaxine Pty Ltd NCT05148871

Активно (без набиране) Фаза 2/3

Setrusumab vs Placebo for Osteogenesis Imperfecta

Osteogenesis Imperfecta

The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.

Начало: 21.02.2022 Край: 01.04.2027 Възраст: 5–25 г. Лечение

Australia, Canada, France +7 Ultragenyx Pharmaceutical Inc NCT05125809

Активно (без набиране) Фаза 1/2

Anakinra for Preterm Infants Pilot

Prematurity; Extreme Inflammation

Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.

Начало: 15.02.2022 Край: 01.03.2025 Възраст: 24–28 г. Лечение

Australia, New Zealand Monash Medical Centre NCT05280340

Активно (без набиране) Фаза 1/2

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Hereditary Angioedema HAE

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

Начало: 15.02.2022 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, Spain, United States BioMarin Pharmaceutical NCT05121376

Активно (без набиране)

Collection of Head Images During Radiotherapy

Head and Neck Neoplasms Radiation Therapy Complication

The primary objective of this observational study is to quantify the translation, rotation, and deformation of patient head positions of head and neck cancer patients over the course of a radiation therapy treatment for head and neck cancer. This objective will be achieved by comparing X-ray images collected during each treatment session with those obtained from the planning CT scan. Secondary objectives include (1) the use of the collected X-ray images to develop realistic artificial X-ray images where patient movement can be simulated and (2) to determine whether motion can be detected from individual X-ray images acquired during radiation therapy treatment.

Начало: 14.02.2022 Край: 31.12.2024 Възраст: от 18 г.

Australia University of Sydney NCT05218824

Активно (без набиране)

LIFE-BTK PK Sub-study

Critical Limb Ischemia (CLI)

LIFE-BTK PK is a prospective, single-arm, open-label, non-blinded, non-randomized sub-study of LIFE-BTK Randomized Controlled Trial (NCT04227899), that will enroll approximately 7 subjects in the United States (US) and outside the US with a maximum of 5 sites in the US. Of the 7 subjects planned to be enrolled, 4 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom drug-coated balloons (DCB) were not used; 3 subjects will be treated with Esprit BTK in below the knee artery(ies) in whom DCB were used for treatment of inflow disease.

Начало: 10.02.2022 Край: 22.02.2028 Възраст: от 18 г. Лечение

Australia, Taiwan, United States Abbott Medical Devices NCT05208905

Активно (без набиране) Фаза 3

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Atherosclerotic Cardiovascular Disease

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy.

Начало: 07.02.2022 Край: 01.11.2026 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +19 NewAmsterdam Pharma NCT05202509

Активно (без набиране) Фаза 3

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.

Начало: 07.02.2022 Край: 02.07.2030 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +16 AstraZeneca NCT05221840

Активно (без набиране) Фаза 3

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Endometrial Neoplasms

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).

Начало: 03.02.2022 Край: 27.05.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +23 Merck Sharp & Dohme LLC NCT05173987

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).

Начало: 02.02.2022 Край: 01.07.2027 Възраст: 18–89 г. Лечение

Australia, Belgium, Brazil +16 UCB Biopharma SRL NCT05063162

Активно (без набиране) Фаза 1/2

A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)

Advanced MTAP-null Solid Tumors

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.

Начало: 01.02.2022 Край: 29.05.2028 Възраст: 18–100 г. Лечение

Australia, Belgium, Canada +10 Amgen NCT05094336

Активно (без набиране) Фаза 1/2

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Cataract

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

Начало: 27.01.2022 Край: 01.09.2026 Възраст: от 18 г. Превенция

Australia Nacuity Pharmaceuticals, Inc. NCT05026632

Активно (без набиране)

ADH1 and ADH2 Disease Monitoring Study (DMS)

Autosomal Dominant Hypocalcemia

A global, multi-center, Disease Monitoring Study (DMS) in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1) or Autosomal Dominant Hypocalcemia Type 2 (ADH2) designed to characterize ADH1 and ADH2 disease presentation and progression through retrospective (past) and longitudinal prospective (over time into the future) data collection.

Начало: 20.01.2022 Край: 01.12.2028 Възраст: до 90 г.

Australia, Belgium, Canada +9 Calcilytix Therapeutics, Inc., a BridgeBio company NCT05227287

Активно (без набиране) Фаза 3

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Начало: 19.01.2022 Край: 30.10.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Bosnia and Herzegovina +23 Janssen Research & Development, LLC NCT05197049

Активно (без набиране)

Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.

Non-melanoma Skin Cancer

Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study.

Начало: 17.01.2022 Край: 15.05.2027 Възраст: от 18 г. Лечение

Australia, Germany, South Africa +1 OncoBeta Therapeutics NCT05135052

1 … 120 121 122 123 124 … 154